Article

Small molecule inducers of angiogenesis for tissue engineering.

Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia 22908, USA.
Tissue Engineering (Impact Factor: 4.25). 08/2006; 12(7):1903-13. DOI: 10.1089/ten.2006.12.1903
Source: PubMed

ABSTRACT Engineering of implantable tissues requires rapid induction of angiogenesis to meet the significant oxygen and nutrient demands of cells during tissue repair. To this end, our laboratories have utilized medicinal chemistry to synthesize non-peptide-based inducers of angiogenesis to aid tissue engineering. In this study, we describe the evaluation of SC-3-149, a small molecule compound with proliferative effects on vascular endothelial cells. Specifically, exogenous exposure of SC-3-149 induced an 18-fold increase in proliferation of human microvascular endothelial cells in vitro at low micromolar potency by day 14 in culture. Moreover, SC-3-149 significantly increased the formation of endothelial cord and tubelike structures in vitro, and improved endothelial scratch wound healing within 24 h. SC-3-149 also significantly inhibited vascular endothelial cell death owing to serum deprivation and high acidity (pH 6). Concurrent incubation of SC-3-149 with vascular endothelial growth factor increased cell survivability under serum-deprived conditions by an additional 7%. In addition, in vivo injection of SC-3-149 into the rat mesentery produced qualitative increases in microvessel length density. Taken together, our studies suggest that SC-3-149 and its analogs may serve as promising new angiogenic agents for targeted drug delivery and therapeutic angiogenesis in tissue engineering.

0 Bookmarks
 · 
84 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Electrospun nanofiber matrices have attracted a great deal of attention as matrices for skin repair and regeneration. The current manuscript reports the fabrication and characterization of a bioactive polycaprolactone (PCL) fiber matrix for its ability to deliver multiple factors. Bioactive PCL matrices were created by incorporating a model angiogenic factor and a model antibiotic drug. Chitosan coating on the fiber matrices significantly improved the ability to hold moisture and contributed to antibiotic activity. These fiber matrices have a modulus of 5.8 ± 1.3 MPa and matrices subjected to degradation over 4 weeks did not lose their tensile properties due to slow degradation rate. Chitosan coating avoided the initial burst release commonly associated with fiber matrices and only 60% of the encapsulated drug was released over a period of 15 days. Control PCL-chitosan matrices were able to reduce Staphylococcus aureus (S. aureus) growth both in static and dynamic condition as compared to formulations with 50 mg gentamicin. In general, all the fiber matrices were able to support fibroblast growth and maintained normal cell morphology. Such bioactive bandages may serve as versatile and less expensive alternatives for the treatment of complex wounds. © 2015 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2015, 132, 41879.
    Journal of Applied Polymer Science 04/2015; 132(16). DOI:10.1002/app.41879 · 1.40 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Musculoskeletal regenerative engineering approach using small bioactive molecules in conjunction with advanced materials has emerged as a highly promising strategy for musculoskeletal repair and regeneration. Advanced biomaterials technologies have revealed nanofiber-based scaffolds for musculoskeletal tissue engineering as vehicles for the controlled delivery of small molecule drugs. This review article highlights recent advances in nanofiber-based delivery of small molecules for musculoskeletal regenerative engineering. The article concludes with perspectives on the challenges and future directions.
    Nanomedicine Nanotechnology Biology and Medicine 06/2014; DOI:10.1016/j.nano.2014.05.013 · 5.98 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Stimulation of bone regeneration using growth factors is a promising approach for musculoskeletal regenerative engineering. Common limitations with protein growth factors are high manufacturing costs, protein instability, contamination issues, and unwanted immunogenic responses of the host. New strategies for bone regeneration that obviate these problems can have a significant impact on the treatment of skeletal injury and diseases. Over the past decade, a large number of small molecules with the potential of regenerating skeletal tissue have been reported in the literature. Here, we review this literature, paying specific attention to the prospects for small molecule-based bone-regenerative engineering. We also review the preclinical study of small molecules associated with bone regeneration.
    Drug discovery today 06/2014; DOI:10.1016/j.drudis.2014.01.012 · 6.63 Impact Factor